In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent leflunomide to its active α-cyanoenol metabolite A771726: Mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes

Drug Metabolism and Disposition

Volumn 31, Issue 10, 2003, Pages 1240-1250

  Kalgutkar, Amit S ^a   Nguyen, Hang T ^a   Vaz, Alfin D N ^a   Doan, Anke ^a   Dalvie, Deepak K ^a   McLeod, Dale G ^a   Murray, John C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOXIME; ANTIINFLAMMATORY AGENT; CYTOCHROME P450; DRUG METABOLITE; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; TERIFLUNOMIDE;

ALBUMIN BLOOD LEVEL; ARTICLE; CATALYSIS; CHEMICAL BOND; DEHYDRATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; HUMAN; LIVER MICROSOME; NONHUMAN; PH; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; TEMPERATURE DEPENDENCE;

ANILINE COMPOUNDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOCHROME P-450 ENZYME SYSTEM; DESICCATION; HUMANS; HYDROXYBUTYRATES; ISOXAZOLES; MALE; MICROSOMES, LIVER; OXIMES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0141569613     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.10.1240     Document Type: Article

References (32)

1. Bertolini G, Aquino M, Biffi M, d'Atri G, Di Pierro F, Ferrario F, Mascagni P, Somenzi F, Zaliani A, and Leoni F (1997) A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug. J Med Chem 40:2011-2016.
2. Boucher JL, Delaforge M, and Mansuy D (1994) Dehydration of alkyl- and arylaldoximes as a new cytochrome P450-catalyzed reaction: mechanism and stereochemical characteristics. Biochemistry 33:7811-7818.
3. Cillar JA, Martin N, Seoane C, and Soto JL (1985) Ring transformation of isoxazoles into furan and pyran derivatives. J Chem Soc Perkin Trans 1:2581-2584.
4. Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, Obach RS, and O'Donnell JP (2002) Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem Res Toxicol 15:269-299.
5. Davis JP, Cain GA, Pitts WJ, Magolda RL, and Copeland RA (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35:1270-1273.
6. De Munno A, Bertini V, and Lucchesini F (1977) On the base catalysed ring opening of 3-unsubstituted isoxazoles. Derivatives of 4- and 5-phenylisoxazole. J Chem Soc Perkin Trans 2;1121-1124.
7. Fitzpatrick FA, Liggett WF, and Wynalda MA (1984) Albumin-eicosanoid interactions. J Biol Chem 259:2722-2727.
8. Kitamura S, Sugihara K, Kuwasako M, and Tatsumi K (1996) The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol 49:253-256.
9. Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, and Marnett LJ (2001) Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem 276:36993-36998.
10. Kuo EA, Hambleton PT, Kay DP, Evans PL, Matharu SS, Little E, McDowall N, Jones CB, Hedgecock CJ, Yea CM, et al. (1996) Synthesis, structure-activity relationships and pharmacokinetic properties of dihydrborotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3′-methyl-4′ -(trifluoromethyl)phenyl] propenamide and related compounds. J Med Chem 39:4608-4621.
11. Kwon C, Maddison K, LoCastro L, and Borch RF (1987) Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin. Cancer Res 47:1505-1508.
12. Lucian J, Dias VC, LeGatt DF, and Yatscoff RW (1995) Blood distribution and single-dose pharmacokinetics of leflunomide. Ther Drug Monit 17:454-459.
13. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, and Heykants J (1993) Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos 21:1134-1141.
14. Mathews JM, Black SR, and Burka LT (1998) Disposition of butanal oxime in rat following oral, intravenous and dermal administration. Xenobiotica 28:767-777.
15. McGregor DN, Corbin U, Swigor JE, and Cheney LC (1969) Synthesis of isoxazoles. The transformation of isoxazoles into isothiazoles. Tetrahedron 25:389-395.
16. Mutlib AE, Strupczewski JT, and Chesson SM (1995) Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Drug Metab Dispos 23:951-964.
17. Nakasa H, Komiya M, Ohmori S, Kitada M, Rikihisa T, and Kanakubo Y (1992) Formation of reductive metabolite, 2-sulfamoylacetylphenol, from zonisamide in rat liver microsomes. Res Commun Chem Pathol Pharmacol 77:31-41.
18. Nakasa H, Komiya M, Ohmori S, Rikihisa T, and Kitada M (1993a) Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. Drug Metab Dispos 21:777-781.
19. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, and Kitada M (1993b) Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol 44:216-221.
20. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
21. Perez C, Janin YL, and Grierson DS (1996) Isoxazoles as latent α-cyanoaldehydes: construction of the indolo[2,3-a]quinolizine ring system. Tetrahedron 52:987-992.
22. Peters T (1996) All about Albumin: Biochemistry, Genetics and Medical Applications, Academic Press, San Diego, CA.
23. Prakash A, and Jarvis B (1999) Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 58:1137-1164.
24. Roller SG, Dieckhaus CM, Santos WL, Sofia RD, and Macdonald TL (2002) Interaction between human serum albumin and the felbamate metabolites 4-hydroxy-5-phenyl-[1,3]oxazinan-2-one and 2-phenylpropenal. Chem Res Toxicol 15:815-824.
25. Rozman B (2002) Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 41:421-430.
26. Silva HT and Morris RM (1997) Leflunomide and malononitriles. Expert Opin Investig Drugs 6:51-64.
27. Sjogren EB, Rider MA, Nelson PH, Bingham S Jr, Poulton AL, Emanuel MA, and Komuniecki R (1991) Synthesis and biological activity of a series of diaryl-substituted α-cyano-β-hydroxypropenamides, a new class of anthelmintic agents. J Med Chem 34:3295-3301.
28. Stiff DD and Zemaitis MA (1990) Metabolism of the anticonvulsant agent zonisamide in the rat. Drug Metab Dispos 18:888-894.
29. Sugihara K, Kitamura S, and Tatsumi K (1996) Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Dispos 24:199-202.
30. Wakefield BJ and Wright DJ (1979) Isoxazole chemistry since 1963. Adv Heterocycl Chem 25:147-204.
31. Walker JE (1976) Lysine residue 199 of human serum albumin is modified by acetylsalicylic acid. FEBS Lett 66:173-175.
32. Zipse H, Apaydin G, and Houk KN (1995) A quantum mechanical and statistical mechanical exploration of the thermal decarboxylation of Kemp's other acid (benzisoxazole-3-carboxylic acid). The influence of solvation on the transition state geometries and kinetic isotope effects of a reaction with an awesome solvent effect. J Am Chem Soc 117:8608-8617.